Stock AnalizPenumbra Inc PEN
Medical/Dental Instruments · IPO 2015 · data as of November 13, 2026
Penumbra Inc (PEN) is a healthcare company listed in the US with a market value of about $12.6B. In the twelve months to September 30, 2026 it had revenue of $1.6B and net income of $157M, a net margin of 10.1%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is financial health (5/5); the weakest is value (0/5).
Key numbers: a P/E of 80.8, a price to free cash flow of 63.1, 5-year revenue growth of 20% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 76% below the current price.
Score: 2.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6B | $1.4B | $1.2B | $1.1B | $847M | $748M | $560M | $547M | $445M | $334M | $263M |
| Net income | $157M | $178M | $14M | $91M | -$2M | $5M | -$16M | $48M | $7M | $5M | $15M |
| Free cash flow | $200M | $175M | $147M | $82M | -$75M | -$12M | -$58M | $5M | $19M | $159000 | -$26M |
| EPS (diluted) | $3.97 | $4.52 | $0.36 | $2.32 | $-0.05 | $0.14 | $-0.44 | $1.34 | $0.18 | $0.13 | $0.44 |
| Net margin | 10.1% | 12.7% | 1.2% | 8.6% | -0.2% | 0.7% | -2.8% | 8.8% | 1.5% | 1.4% | 5.6% |
| ROIC | — | 10.1% | 0.5% | 4.2% | 0.4% | -0.5% | -2.9% | 8.3% | -0.1% | 0.2% | -0.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $362.54, 13% above the current price; targets range from $320.00 to $374.00; the consensus rating is “Hold”; expected EPS is $4.91 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Penumbra’s P/E ratio?
About 80.8, based on the last twelve months of diluted earnings per share (forward P/E about 53.8).
Is Penumbra stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 76% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Penumbra pay a dividend?
Not currently.
Is Penumbra a good stock to buy?
We do not give buy or sell advice. Penumbra scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.